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have been reported to date. Transient Grade 1 lymphade-
nopathy has been reported for 6 HV across multiple dose
levels. No anti-CDX-301 antibodies have been detected
through end of study day 34 in Cohorts 1-5; testing for
Cohorts 6-7 is ongoing. White blood cell count (WBC) and
monocytes increased in all HV; peak levels were observed
around Day 10 and generally returned to baseline by Day 34.
At doses above 3 mcg/kg, there was no clear dose
response; mean maximum % change from baseline for
Cohorts 3-6 ¼ 99% (range: 43-224%) for WBC and 784%
(range: 264-1400%) for monocytes. In-depth phenotypic
and/or functional analysis of hematopoietic stem cells and
dendritic cell subsets are planned. Data from this current
Phase 1 trial are consistent with previous studies showing
that rhFlt3L is well-tolerated and can safely and effectively
mobilize hematopoietic cell populations. Data from this trial
are expected to deﬁne the dosing regimen for planned trials
of CDX-301 in allogeneic hematopoietic stem cell trans-
plantation (HSCT) and immunotherapy.8
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Patients (pts) with acute myeloid leukemia (AML) who
relapse after allogeneic hematopoietic cell transplantation
(AlloHCT) have limited treatment options and their expected
survival is poor. Prognostic factors for survival in pts
relapsing after AlloHCT are unclear. We therefore analyzed
response to salvage therapy and survival. Three hundred and
forty eight pts with AML underwent AlloHCT between 2000-
2012 using umbilical cord blood (UCB, 222) or an HLA
matched related donor (RD, 126). Relapse after AlloHCT
occurred in 104 pts: 72 of 222 after UCB and 32 of 126 after
RD transplantation at a median time of 152 days (range, 77-
322). UCB and RD pts were comparable in their demographic
and disease characteristics including: cytogenetic risk,
presence of GVHD at relapse, proportion receiving immu-
nosuppressive therapy (IST) at relapse, time to relapse,
relapse site (systemic vs. isolated extramedullary), bone
marrow (BM) or percent of peripheral blood blasts at relapse,
BM donor chimerism, and concurrent infectious or GVHD-
related complications. Compared to RD, more UCB recipients
underwent reduced intensity HCT (68% vs. 41%, p¼0.01), had
active infection (25% vs. 6%, p¼0.03) or acute treatment
related complications (e.g. veno-oclusive disease, kidney
injury, cardiac arrhythmia) (33% vs. 13%, p¼0.04) at the time
of relapse. After relapse, all but 1 patient in each group
underwent IST taper with 3 recipients (2 UCB and 1 RD)achieving a complete remission (CR). In UCB and RD recipi-
ents, post-relapse active therapy consisted of systemic
chemotherapy in 21 and 6 pts, second AlloHCT in 9 and 2 pts,
supportive care in 30 and 6 pts and donor lymphocyte
infusions (DLI)  systemic chemotherapy in 0 and 12,
respectively (with no additional information on 18 pts
[UCB¼12, RD¼6] who were managed elsewhere at the time
of relapse). Survival at 1 year after relapse was 22% for all pts
(19% UCB vs. 28% RD, p¼0.32). Only 25% of pts with post-
relapse therapy achieved subsequent CR (21% UCB vs. 35%
RD, p¼0.16). In multivariable analysis, donor type was not an
independent predictor of post-relapse mortality (HR¼0.9;
95% CI 0.5-1.6, p¼0.72). Post-relapse mortality, however, was
higher in pts with PB blasts above the median (median¼3%;
HR¼3.9; 95% CI 2.2-6.9, p<0.01), active infection (HR¼2.0;
95% CI 1.1-3.9, p¼0.03), and history of other treatment
related complications at relapse (HR¼2.0; 95% CI 1.1-3.4,
p¼0.02). Pts receiving any type of active therapy (chemo-
therapy, DLI or second AlloHCT) at relapse (HR¼0.3; 95% CI
0.2-0.5, p<0.01) had lower mortality. Pts with AML who
relapsed after AlloHCT and were in a clinical condition
sufﬁcient to tolerate any therapeutic option can achieve CR
and enjoy prolonged survival compared to those that receive
supportive therapy. Despite that fact DLI is not generally
available to UCB recipients, salvage therapy with systemic
chemotherapy or second AlloHCT provides similar results.9
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Background: The Myelodysplastic Syndromes (MDS) and
Myeloproliferative Neoplasms (MPN) primarily affect older
patients ineligible for myeloablative allogeneic hematopoi-
etic cell transplantation (allo HCT). The preparative regimen
of Total Lymphoid Irradiation (TLI) and Anti-Thymocyte
Globulin (ATG) permits the establishment of donor hema-
topoiesis that is necessary for the graft versus malignancy
effect but is protective against acute Graft versus Host
Disease (aGVHD), presumably due to the enrichment of tol-
erogenic recipient NK-Tcells (Lowsky et al., NEJM 2005, Kohrt
et al, Blood 2009). Here we report the outcomes of patients
with MDS and MPN treated with TLI-ATG and allo HCT.
Methods and Patients: Patients received TLI (cumulative
dose1200 cGy) and ATG (7.5 mg/kg). GVHD prophylaxis
consisted of Cyclosporine A and Mycophenolate Mofetil. Of
51 consecutive patients treated between August 2004 and
December 2010, the median age was 63 years (range 50-73).
The initial diagnosis was de novoMDS (n¼24), CMML (n¼6),
MPN (n¼8), and therapy-related MDS (t-MDS, n¼13). Among
patients with de novoMDS, the IPSS-R score (Greenberg et al.,
Blood 2012) at the time of HCT was Very High or High (17%),
Intermediate (23%), Low or Very Low (53%) or unknown/
indeterminate (7%). Patients received mobilized peripheral
blood from matched related (45%), 10/10 matched unrelated
(45%), or mismatched unrelated donors (10%).
Results: The median follow up for living patients was 3.2
years (range 1.5-7). The three-year overall survival (OS), non-
relapse mortality (NRM), and event-free survival (EFS) were
42% (95% CI 28-56%), 8% (0.3-15%), and 31% (18-44%),
respectively. The cumulative incidence of aGVHD Grades II-
Table 1
Patient Characteristics
Age (median, range) 71 (70-76)
Male (n, %) 37 (66%)
HCT-CI score (median, range) 1 (0-5)
Disease (n, %)
AML 26 (46%)
MDS 15 (27%)
CLL 5 (9%)
NHL 4 (7%)
ALL 3 (5%)
MPD 2 (4%)
CML 1 (2%)
Donor Type (n, %)
MUD 44 (79%)
MRD 10 (18%)
Mismatched UD 2 (4%)
Conditioning Regimen (n, %)
Busulfan/Fludarabine 53 (93%)
Melphalan/Fludarabine 2 (4%)
Clofarabine/ATG/TLI 1 (2%)
GVHD Prophylaxis (n, %)
CNI þ Siro  MTX 34 (61%)
CNI þ MTX 9 (16%)
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not differ according to allograft source. The three-year
cumulative incidence of Chronic GVHD was 33% (20-47%).
The three-year cumulative incidence of progression was not
signiﬁcantly different for patients with MDS (60%, 95%CI 44-
73%), MPN (88%, 71-95%), or t-MDS (45%, 15-70%). MDS
patients with IPSS-R Very High and High Risk scores all had
progressive disease within the ﬁrst 100 days. In contrast,
patients with Intermediate Risk scores had equivalent
progression-free survival rates with those in the Very Low
and Low risk groups (Hazard Ratio for progression 1.25, 0.36-
4.32). Patients with donor CD15>90% at day 28 (40% of
patients) deﬁned a group with a low likelihood of disease
progression (Odds Ratio 0.20, p¼.01).
Discussion: For patients with MDS and MPN, TLI/ATG
conditioning was associated with low rates of acute GVHD
and NRM. Patients whose IPSS-R scores at the time of HCT
were Intermediate, Low, and Very Low had signiﬁcantly
lower risks of disease progression than those with High or
Very High risk scores, suggesting early transplantation with
TLI/ATG may result in better long-term outcomes.CNI þ ATG þ MTX 7 (13%)
CNI þ MMF 3 (5%)
Other 3 (5%)10
Outcomes of Patients Older Than Age 70 Undergoing
Allogeneic Hematopoietic Stem Cell Transplantation for
Hematologic Malignancies
Andrew M. Brunner 1, Yi-Bin Chen 1, Haesook Kim 2,
Erin Coughlin 1, Edwin P. Alyea III 3, Philippe Armand 3,
Karen Ballen 1, Corey Cutler 3, Bimalangshu R. Dey 1,
Brett Glotzbecker 4, John Koreth 5, Steven L. McAfee 1,
Thomas R. Spitzer 1, Robert J. Soiffer 5, Joseph H. Antin 3,
Vincent T. Ho 3. 1Massachusetts General Hospital, Boston, MA;
2 Biostatistics and Computational Biology, Dana-Farber Cancer
Institute, Boston, MA; 3Hematologic Malignancies, Dana-
Farber Cancer Institute, Boston, MA; 4 Beth Israel Deaconess
Medical Center, Boston, MA; 5Dana-Farber Cancer Institute,
Boston, MA
Allogeneic hematopoietic stem cell transplantation
(HSCT) can achieve durable remissions in a number of
advanced hematologic malignancies. The advent of reduced
intensity conditioning (RIC) regimens has allowed HSCT to be
offered to increasingly older adults. However, little is known
about the safety of HSCT in patients over the age of 70 years.
The purpose of this retrospective study was to describe the
overall outcomes of patients older than age 70 who under-
went HSCT for hematologic malignancies. We identiﬁed 56
consecutive patients age 70 or older who underwent HSCT at
Massachusetts General Hospital or the Dana-Farber Cancer
Institute between January 2007 and July 2012. Patients were
included in this study if age 70 or older on the day of trans-
plantation. All patients met standard institutional criteria for
HSCT eligibility. The majority of patients underwent trans-
plant for acute leukemia or myelodysplastic syndrome (AML
26,MDS15, CLL5,NHL4,ALL3,MPD2,CML1).Median follow-
up for survivors was 15months (range 2-86). Themedian age
at transplantwas71years (range70-76) and66% (37/56)were
male; themedian HCT-CI scorewas 1 (range 0-5). All patients
received RIC regimens with 93% receiving a busulfan / ﬂu-
darabine regimen. All patients receivedperipheral blood stem
cell grafts; 44 froman8/8matchedunrelateddonor (MUD),10
from a matched related donor (MRD), and 2 from a 7/8
matched unrelated donor. 95% of patients received calci-
neurin inhibitor-based GVHD prophylaxis regimens, most in
combination with sirolimus or methotrexate (Table 1). Of
these 56 patients, 2 died prior to engraftment, one from graft
failure and one from disease progression. Of the 46 patientswho experienced a nadir, the median time to neutrophil
engraftment was 13 days (range 2-31). Maximum cumulative
grade II-IV acute GVHD incidence was 13% and grade III-IV
acute GVHD7%. One year cumulative chronicGVHD incidence
was 37%. One-year progression-free survival was 42% and
one-year overall survival was 55%. The cumulative incidence
of relapsewas 34% and non-relapsemortality was 3.6% at day
100 and 5.5% at 1-year after HSCT. HSCT is a safe and effective
option for patients over the age of 70. Further follow-up and
analysis are needed to determine which patients will derive
beneﬁt from allogeneic transplantation; however, for care-
fully selectedelderlypatients, ageover70shouldnotpreclude
consideration of HSCT.11
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Comparisons of myeloablative conditioning versus
reduced intensity conditioning (RIC) demonstrate a tradeoff
between relapse and more toxicity. Dose intensity across RIC
